Microbial Production of Plant-Derived Pharmaceutical Natural Products through Metabolic Engineering: Artemisinin and beyond

Biocatalysis for Green Chemistry and Chemical Process Development

Volumn , Issue , 2011, Pages 173-196

  Dietrich, Jeffrey A ^a   Fortman, J L ^b   Juminaga, Darmawi ^c   Keasling, Jay D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Artemisinin and beyond; As the rate limiting pathway enzyme for amorphadiene biosynthesis; Gene copy numbers of titrating pathway enzymes identifying mevalonate kinase (MK); Microbial production of plant derived pharmaceutical natural products through metabolic engineering; Terpene indole alkaloids expanding upon mevalonate pathway

Indexed keywords

EID: 84881543561     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118028308.ch7     Document Type: Chapter

References (66)

1. Solecki R. Shanidar IV, a Neanderthal flower burial in northern Iraq. Science 1975;190:880-881.
2. Leroi-Gourhan A. The flowers found with Shanidar IV, a Neanderthal burial in Iraq. Science 1975;190:562-564.
3. Newman J, Cragg G, Snader K. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037.
4. Saklani A, Kutty S. Plant-derived compounds in clinical trials. Drug Discov Today 2008;13:161-171.
5. Andrew McWilliams. Plant-derived drugs: products, technology, applications. BCC Research; 2006.
6. Horwitz SB. How to make taxol from scratch. Nature 1994;367:593-594.
7. Jennewein S, Croteau R. Taxol: biosynthesis, molecular genetics, and biotechnological applications. Appl Microbiol Biotechnol 2001;57:13-19.
8. Noble R. The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochem Cell Biol 1990;68:1344-1351.
9. Schoemaker HE, Mink D, Wubbolts MG. Dispelling the myths-biocatalysis in industrial synthesis. Science 2003;299:1694-1697.
10. Conolly J, Hill R. Dictionary of terpenoids. London: Chapman & Hall; 1991.
11. Korenromp E, Nahlen B, Wardlaw T, Young M. World Malaria Report: World Health Organization (WHO), Roll Back Malaria (RBM) and United Nations Children's Fund (UNICEF). World Health Organization; Geneva, Switzerland: 2005.
12. Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JRA, Stein C, Nahlen BL, Bryce J, Black RE, Steketee RW. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 2006;35:691-704.
13. Gallup J, Sachs J. The economic burden of malaria. Am J Trop Med Hyg 2001;64:85-96.
14. van Lieshout M, Kovats RS, Livermore MTJ, Martens P. Climate change and malaria: analysis of the SRES climate and socio-economic scenarios. Glob Environ Change 2004;14:87-99.
15. Olumese P. Guidelines for the treatment of Malaria. World Health Organization; Geneva, Switzerland: 2006.
16. Benatar S. Distributive justice and clinical trials in the third world. Theor Med 2001;22:169-176.
17. Novartis. Novartis accelerates production of life-saving malaria treatment Coartem. Basel, Switzerland: Press Release; 2006.
18. Covello PS. Making artemisinin. Phytochemistry 2008;69:2881-2885.
19. Cohen JM, Singh I, O'Brien ME. Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies. Malar J 2008;7: 200.
20. Hale V, Keasling JD, Renninger N, Diagana TT. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. Am J Trop Med Hyg 2007;77:198-202.
21. Graham IA, Besser K, Blumer S, Branigan CA, Czechowski T, Elias L, Guterman I, Harvey D, Isaac PG, Khan AM, Larson TR, Pawson YLT, Penfield T, Rae AM, Rathbone DA, Reid S, Ross J, Smallwood MF, Vyas VSTTD, Winzer T, Bowles D. The genetic map of Artemisia annua L. identifies loci affecting yield of the antimalarial drug artemisinin. Science 2010;327:328-331.
22. Lapkin AA, Plucinski PK, Cutler M. Comparative assessment of technologies for extraction of artemisinin. J Nat Prod 2006;69:1653-1664.
23. Rohmer M, Knani M, Simonin P, Sutter B, Sahm H. Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem J 1993: 295.
24. Martin VJJ, Pitera DJ, Withers ST, Newman JD, Keasling JD. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat Biotechnol 2003;21:796-802.
25. Ohnuma S, Narita K, Nakazawa T, Ishida C, Takeuchi Y, Ohto C, Nishino T. A role of the amino acid residue located on the fifth position before the first aspartate-rich motif of farnesyl diphosphate synthase on determination of the final product. J Biol Chem 1996;271:30748-30754.
26. Lee PC, Petri R, Mijts BN, Watts KT, Schmidt-Dannert C. Directed evolution of Escherichia coli farnesyl diphosphate synthase (IspA) reveals novel structural determinants of chain length specificity. Metab Eng 2005;7:18-26.
27. Ohnuma S, Nakazawa T, Hemmi H, Hallberg A, Koyama T, Ogura K, Nishino T. Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis. J Biol Chem 1996;271:10087-10095.
28. Reiling KK, Yoshikuni Y, Martin VJJ, Newman J, Bohlmann J, Keasling JD. Mono and diterpene production in Escherichia coli . Biotechnol Bioeng 2004;87:200-212.
29. Roth R, Acton N. A simple conversion of artemisinic acid into artemisinin. J Nat Prod 1989;52:1183-1185.
30. Ro D-K, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J, Chang MCY, Withers ST, Shiba Y, Sarpong R, Keasling JD. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 2006;440:940-943.
31. Wentzel A, Ellingsen TE, Kotlar H-K, Zotchev SB, Throne-Holst M. Bacterial metabolism of long-chain n-alkane. Appl Microbiol Biotechnol 2007;76:1209-1221.
32. Salis HM, Mirsky EA, Voigt CA. Automated design of synthetic ribosome binding sites to control protein expression. Nat Biotechnol 2009;27:946-950.
33. Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Metab Eng 2009;11:13-19.
34. Pfleger BF, Pitera DJ, Smolke CD, Keasling JD. Combinatorial engineering of intergenic regions in operons tunes expression of multiple genes. Nat Biotechnol 2006;24:1027-1032.
35. Dueber JE, Wu GC, Malmirchegini GR, Moon TS, Petzold CJ, Ullal AV, Prather KLJ, Keasling JD. Synthetic protein scaffolds provide modular control over metabolic flux. Nat Biotechnol 2009;27:753-759.
36. Carter OA, Peters RJ, Croteau R. Monoterpene biosynthesis pathway construction in Escherichia coli . Phytochemistry 2003;64:425-433.
37. Chang MCY, Eachus RA, Trieu W, Ro D-K, Keasling JD. Engineering Escherichia coli for production of functionalized terpenoids using plant P450s. Nat Chem Biol 2007;3:274-277.
38. Dietrich JA, Yoshikuni Y, Fisher KJ, Woolard FX, Ockey D, McPhee DJ, Renninger NS, Chang MCY, Baker D, Keasling JD. A bovel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450BM3. ACS Chem Biol 2009;4:261-267.
39. Shiba Y, Paradise EM, Kirby J, Ro D, Keasling JD. Engineering of the pyruvate dehydrogenase bypass in Saccharomyces cerevisiae for high-level production of isoprenoids. Metab Eng 2007;9:160-168.
40. Ro D, Ouellet M, Paradise EM, Burd H, Eng D, Paddon CJ, Newman JD, Keasling JD. Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid. BMC Biotechnol 2008;8:83.
41. Newman JD, Marshall J, Chang M, Nowroozi F, Paradise E, Pitera D, Newman KL, Keasling JD. High-level production of amorpha-4,11-diene in a two-phase partitioning bioreactor of metabolically engineered Escherichia coli . Biotechnol Bioeng 2006;95:684-691.
42. de Bont J. Solvent-tolerant bacteria in biocatalysis. Trends Biotechnol 1998;16:493-499.
43. Nielsen DR, Leonard E, Yoon S, Tseng H, Yuan C, Prather KLJ. Engineering alternative butanol production platforms in heterologous bacteria. Metab Eng 2009;11:262-273.
44. Chang C, Cen P, Ma X. Levulinic acid production from wheat straw. Bioresour Technol 2007;98:1448-1453.
45. Martin CH, Prather KLJ. High-titer production of monomeric hydroxyvalerates from levulinic acid in Pseudomonas putida. J Biotechnol 2009;139:61-67.
46. O'Connor SE, Maresh JJ. Chemistry and biology of monoterpene indole alkaloid biosynthesis. Nat Prod Rep 2006;23:532-547.
47. van Der Heijden R, Jacobs DI, Snoeijer W, Hallard D, Verpoorte R. The Catharanthus alkaloids: pharmacognosy and biotechnology. Curr Med Chem 2004;11:607-628.
48. deWaal A, Meijer AH, Verpoorte R. Strictosidine synthase from Catharanthus roseus: purification and characterization of multiple forms. Biochem J 1995;306:571-580.
49. de Luca V, Marineau C, Brisson N. Molecular cloning and analysis of cDNA encoding a plant tryptophan decarboxylase: comparison with animal dopa decarboxylases. Proc Natl Acad Sci USA 1989;86:2582-2586.
50. Sprenger GA. From scratch to value: engineering Escherichia coli wild type cells to the production of L-phenylalanine and other fine chemicals derived from chorismate. Appl Microbiol Biotechnol 2007;75:739-749.
51. Ikeda M. Towards bacterial strains overproducing L-tryptophan and other aromatics by metabolic engineering. Appl Microbiol Biotechnol 2006;69:615-626.
52. Herrmann K, Weaver L. The shikimate pathway. Annu Rev Plant Physiol Plant Mol Biol 1999;50:473-503.
53. Dosselaere F, Vanderleyden J. A metabolic node in action: chorismate-utilizing enzymes in microorganisms. Crit Rev Microbiol 2001;27:75-131.
54. Krämer M, Bongaerts J, Bovenberg R, Kremer S, Müller U, Orf S, Wubbolts M, Raeven L. Metabolic engineering for microbial production of shikimic acid. Metab Eng 2003;5:277-283.
55. Sariaslani FS. Development of a combined biological and chemical process for production of industrial aromatics from renewable resources. Annu Rev Microbiol 2007;61:51-69.
56. Gunsalus R, Yanofsky C. Nucleotide sequence and expression of Escherichia coli trpR, the structural gene for the trp aporepressor. Proc Natl Acad Sci USA 1980;77:7117-7121.
57. Pittard J, Camakaris H, Yang J. The TyrR regulon. Mol Microbiol 2005;55:16-26.
58. Báez-Viveros JL, Osuna J, Hernández-Chávez G, Soberón X, Bolívar F, Gosset G. Metabolic engineering and protein directed evolution increase the yield of Lphenylalanine synthesized from glucose in Escherichia coli . Biotechnol Bioeng 2004;87:516-524.
59. Berry A. Improving production of aromatic compounds in Escherichia coli by metabolic engineering. Trends Biotechnol 1996;14:250-256.
60. Shukla AK, Shasany AK, Gupta MM, Khanuja SPS. Transcriptome analysis in Catharanthus roseus leaves and roots for comparative terpenoid indole alkaloid profiles. J Exp Bot 2006;57:3921-3932.
61. Murata J, Bienzle D, Brandle JE, Sensen CW, Luca VD. Expressed sequence tags from Madagascar periwinkle (Catharanthus roseus). FEBS Lett 2006;580: 4501-4507.
62. Rischer H, Orešič M, Seppänen T, Katajamaa M, Lammertyn F, Ardiles W, Montagu MCEV, Inzé D, Oksman-Caldentey K-M, Goossens A. Gene-to-metabolite networks for terpenoid indole alkaloid biosynthesis in Catharanthus roseus cells. Proc Natl Acad Sci USA 2006;103:5614-5619.
63. Sato F, Inui T, Takemura T. Metabolic engineering in isoquinoline alkaloid biosynthesis. Curr Pharm Biotechnol 2007;8:211-218.
64. Datamonitor. Forecast insight: opioids-saturation limits the commercial potential of individual brands; 2009.
65. Hawkins KM, Smolke CD. Production of benzylisoquinoline alkaloids in Saccharomyces cerevisiae. Nat Chem Biol 2008;4:564-573.
66. Minami H, Kim J-S, Ikezawa N, Takemura T, Katayama T, Kumagai H, Sato F. Microbial production of plant benzylisoquinoline alkaloids. Proc Natl Acad Sci USA 2008;105:7393-7398.